Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Liver fibrosis occurs during wound healing after repeated liver injury and is characterized by extensive extracellular matrix deposition. We previously identified hyaluronan synthase 2 (HAS2) as a driver of liver fibrosis and hepatic stellate cell (HSC) activation. Developing strategies to suppress HSC activation is key to alleviating liver fibrosis, and HAS2 is an attractive candidate for intervention. To gain insight into the molecular function of HAS2, we investigated its posttranscriptional regulation. We found that miR-200c directly targets the 3’ untranslated regions of HAS2. Moreover, miR-200c and HAS2 were inversely expressed in fibrotic human and mouse livers. After establishing the direct interaction between miR-200c and HAS2, we investigated the functional outcome of regulating HAS2 expression in three murine models: CCl4-induced acute liver injury, CCl4-induced chronic liver fibrosis, and bile duct ligation-induced liver fibrosis. Hepatic Has2 expression was induced by acute and chronic CCl4 treatment. In contrast, miR-200c expression was decreased after CCl4 treatment. HSC-specific Has2 deletion reduced the expression of inflammatory markers and infiltration of macrophages in the models. Importantly, hyaluronidase-2 (HYAL2) but not HYAL1 was overexpressed in fibrotic human and murine livers. HYAL2 is an enzyme that can cleave the extracellular matrix component hyaluronan. We found that low-molecular-weight hyaluronan stimulated the expression of inflammatory genes. Treatment with the HA synthesis inhibitor 4-methylumbelliferone alleviated bile duct ligation-induced expression of these inflammatory markers. Collectively, our results suggest that HAS2 is negatively regulated by miR-200c and contributes to the development of acute liver injury and chronic liver inflammation via hyaluronan-mediated immune signaling.
Abstract
Liver fibrosis occurs during wound healing after repeated liver injury and is characterized by extensive extracellular matrix deposition. We previously identified hyaluronan synthase 2 (HAS2) as a driver of liver fibrosis and hepatic stellate cell (HSC) activation. Developing strategies to suppress HSC activation is key to alleviating liver fibrosis, and HAS2 is an attractive candidate for intervention. To gain insight into the molecular function of HAS2, we investigated its posttranscriptional regulation. We found that miR-200c directly targets the 3’ untranslated regions of HAS2. Moreover, miR-200c and HAS2 were inversely expressed in fibrotic human and mouse livers. After establishing the direct interaction between miR-200c and HAS2, we investigated the functional outcome of regulating HAS2 expression in three murine models: CCl4-induced acute liver injury, CCl4-induced chronic liver fibrosis, and bile duct ligation-induced liver fibrosis. Hepatic Has2 expression was induced by acute and chronic CCl4 treatment. In contrast, miR-200c expression was decreased after CCl4 treatment. HSC-specific Has2 deletion reduced the expression of inflammatory markers and infiltration of macrophages in the models. Importantly, hyaluronidase-2 (HYAL2) but not HYAL1 was overexpressed in fibrotic human and murine livers. HYAL2 is an enzyme that can cleave the extracellular matrix component hyaluronan. We found that low-molecular-weight hyaluronan stimulated the expression of inflammatory genes. Treatment with the HA synthesis inhibitor 4-methylumbelliferone alleviated bile duct ligation-induced expression of these inflammatory markers. Collectively, our results suggest that HAS2 is negatively regulated by miR-200c and contributes to the development of acute liver injury and chronic liver inflammation via hyaluronan-mediated immune signaling.
참고문헌 (47)
- Collaborators, G. B. D. C., "The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet Gastroenterol. Hepatol, 5, pp.245~266 (2020)
- Yang, L., "Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1", Gastroenterology, 144, pp.1042~1054 (2013)
- Gyorfi, A. H., "Targeting TGF-beta signaling for the treatment of fibrosis", Matrix Biol, 68-69, pp.8~27 (2018)
- Butz, H., "Crosstalk between TGF-beta signaling and the microRNA machinery", Trends Pharmacol. Sci, 33, pp.382~393 (2012)
- Wang, B., "miR-200a Prevents renal fibrogenesis through repression of TGFbeta2expression", Diabetes, 60, pp.280~287 (2011)
- Gregory, P. A., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1", Nat. Cell Biol, 10, pp.593~601 (2008)
- Carthew, R. W., "Origins and Mechanisms of miRNAs and siRNAs", Cell, 136, pp.642~655 (2009)
- Yang, Y. M., "Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid", Hepatology, 56, pp.2209~2220 (2012)
- Yang, Y. M., "Galpha12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma", Oncogene, 34, pp.2910~2921 (2015)
- Karakatsanis, A., "Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance", Mol. Carcinog, 52, pp.297~303 (2013)
- Hur, K., "MicroRNA-200c modulates epithelial-to-mesenchymal transition(EMT)in human colorectal cancer metastasis", Gut, 62, pp.1315~1326 (2013)
- Luo, C., "MicroRNA-200c expression is decreased in hepatocellular carcinoma and associated with poor prognosis", Clin. Res. Hepatol. Gastroenterol, 43, pp.715~721 (2019)
- Yang, S., "Participation of miR-200 in pulmonary fibrosis", Am. J. Pathol, 180, pp.484~493 (2012)
- Berasain, C., "Expression of Wilms’ tumor suppressor in the liver with cirrhosis : relation to hepatocyte nuclear factor 4 and hepatocellular function", Hepatology, 38, pp.148~157 (2003)
- Yang, Y. M., "Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis", Sci. Transl. Med, 11, pp.eaat9284~ (2019)
- Lagendijk, A. K., "MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production", Circ. Res, 109, pp.649~657 (2011)
- Jiang, D., "Hyaluronan as an immune regulator in human diseases", Physiol. Rev, 91, pp.221~264 (2011)
- Schinzel, R. T., "The hyaluronidase, TMEM2, promotes ER homeostasis and longevity independent of the UPR(ER)", Cell, 179, pp.1306~1318.e18 (2019)
- McKee, C. M., "Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44", J. Clin. Invest, 98, pp.2403~2413 (1996)
- Seki, E., "CCR1 and CCR5 promote hepatic fibrosis in mice", J. Clin. Invest, 119, pp.1858~1870 (2009)
- Heinrichs, D., "The chemokine CCL3 promotes experimental liver fibrosis in mice", PLoS ONE, 8, pp.e66106~ (2013)
- Seki, E., "TLR4 enhances TGF-beta signaling and hepatic fibrosis", Nat. Med, 13, pp.1324~1332 (2007)
- Vuppalanchi, R., "Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis", PLoS ONE, 8, pp.e74471~ (2013)
- Yoon Mee Yang, "Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L -amino acid-defined diet-induced murine model", Archives of Pharmacal Research, 44(2), pp.230~240 (2021), 대한약학회[DOI]
- Liang, J., "Hyaluronan as a therapeutic target in human diseases", Adv. Drug Deliv. Rev, 97, pp.186~203 (2016)
- Jiang, D., "Regulation of lung injury and repair by Toll-like receptors and hyaluronan", Nat. Med, 11, pp.1173~1179 (2005)
- Jiang, J. X., "Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK", STAT and Akt, J. Hepatol, pp.2009, 51[DOI]
- Zhan, S. S., "Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo", Hepatology, 43, pp.435~443 (2006)
- Krenkel, O., "Liver macrophages in tissue homeostasis and disease", Nat. Rev. Immunol, 17, pp.306~321 (2017)
- Wang, S., "Hepatic fibrosis: a convergent response to liver injury that is reversible", J. Hepatol, 73, pp.210~211 (2020)
- Xie, T., "Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis", J. Clin. Invest, 126, pp.3063~3079 (2016)
- Liu, J., "Sonic hedgehog signaling directly targets Hyaluronic Acid Synthase 2, an essential regulator of phalangeal joint patterning", Dev. Biol, 375, pp.160~171 (2013)
- 황성환, "Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases", Archives of Pharmacal Research, 44(6), pp.574~587 (2021), 대한약학회[DOI]
- Mi Jeong Heo, "Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma", Archives of Pharmacal Research, 42(1), pp.48~62 (2019), 대한약학회[DOI]
- Wang, X., "MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases", Gut, 70, pp.784~795 (2021)
- Bartel, D. P., "MicroRNAs : target recognition and regulatory functions", Cell, 136, pp.215~233 (2009)
- Gregory, P. A., "An autocrine TGF-beta", ZEB, Mol. Biol. Cell, pp.2011, 22[DOI]
- Sun, C., "Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion", Nat. Commun, 9, pp.1241~ (2018)
- Tian, H., "miR-200c targets nuclear factor IA to suppress HBV replication and gene expression via repressing HBV Enhancer I activity", Biomed. Pharmacother, 99, pp.774~780 (2018)
- Guo, J., "Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1", Oncotarget, 7, pp.36207~36219 (2016)
- Liu, Y., "Animal models of chronic liver diseases", Am. J. Physiol. Gastrointest. Liver Physiol, 304, pp.G449~G468 (2013)
- Iwaisako, K., "Origin of myofibroblasts in the fibrotic liver in mice", Proc. Natl Acad. Sci. USA, 111, pp.E3297~E3305 (2014)
- Song, Y., "MiR-200c-3p targets SESN1 and represses the IL-6", AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis, 2021, pp.102, 485~493
- Cowman, M. K., "Hyaluronan and hyaluronan fragments", Adv. Carbohydr. Chem. Biochem, 74, pp.1~59 (2017)
- Seki, E., "CCR2 promotes hepatic fibrosis in mice", Hepatology, 50, pp.185~197 (2009)
- Miura, K., "Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2", Am. J. Physiol. Gastrointest. Liver Physiol, 302, pp.G1310~G1321 (2012)
- Anstee, Q. M., "Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis : AURORA Phase 3 study design", Contemp. Clin. Trials, 89, pp.105922~ (2020)